Kamada (KMDA) Non Operating Interest Expenses (2012 - 2026)
Kamada's (KMDA) quarterly Non Operating Interest Expenses came in at -$371000.0 in Q2 2026, down 2750.0% on a YoY basis from $14000.0 in Q2 2025, and down 97.34% quarter-over-quarter from -$188000.0 in Q1 2026.
Analysis
Kamada (KMDA) Non Operating Interest Expenses (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non Operating Interest Expenses for 15 consecutive years, with -$371000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses fell 2750.0% year-over-year to -$371000.0; the trailing twelve-month figure through Jun 2026 stood at -$1.0 million (down 94.57% YoY), and the FY2025 full-year result was -$864000.0, down 30.91% from the prior year.
- Non Operating Interest Expenses eased to -$371000.0 in Q2 2026 per KMDA's latest filing, from -$188000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $2.1 million in Q1 2023 and bottomed at -$2.2 million in Q4 2023.
- Historically, Non Operating Interest Expenses has averaged $533555.6 across 5 years, with a median of $370000.0 in 2023.
- The sharpest annual moves came in 2022 and 2026: Non Operating Interest Expenses surged 4823.81% in 2022, then sank 2750.0% in 2026.
- Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then sank by 309.7% to -$2.2 million in 2023, then soared by 91.59% to -$189000.0 in 2024, then plunged by 37.04% to -$259000.0 in 2025, then tumbled by 43.24% to -$371000.0 in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$371000.0, -$188000.0, and -$259000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | -371,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -371,000.00 |
| Mar 31, 2026 | -188,000.00 |
| Dec 31, 2025 | -259,000.00 |
| Sep 30, 2025 | -221,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | -192,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Sep 30, 2024 | -167,000.00 |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | -2.25 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 726,000.00 |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 2.07 Mn |
| Jun 30, 2022 | 1.62 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 1.36 Mn |
| Sep 30, 2021 | 42,000.00 |